{"id":29129,"date":"2023-09-14T15:42:50","date_gmt":"2023-09-14T14:42:50","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=29129"},"modified":"2025-02-26T15:02:38","modified_gmt":"2025-02-26T14:02:38","slug":"la-resistance-aux-antimicrobiens-une-pandemie-silencieuse","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/","title":{"rendered":"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse"},"content":{"rendered":"\n<p>L\u2019antibior\u00e9sistance, une pand\u00e9mie &#8220;silencieuse&#8221; ou &#8220;n\u00e9glig\u00e9e&#8221;,<sup>1,2<\/sup> est consid\u00e9r\u00e9e par l&#8217;Organisation mondiale de la sant\u00e9 (OMS) comme une menace mondiale pour la sant\u00e9 et le d\u00e9veloppement. Si rien n&#8217;est fait, l\u2019antibior\u00e9sistance pourrait causer la mort de 10 millions de personnes par an d&#8217;ici 2050,<sup>3<\/sup> co\u00fbter 100 milliards de dollars \u00e0 l&#8217;\u00e9conomie mondiale<sup>1<\/sup> et plonger 28 millions de personnes dans l&#8217;extr\u00eame pauvret\u00e9.<sup>4<\/sup> Cette pand\u00e9mie ne peut \u00eatre n\u00e9glig\u00e9e, et nous ne pouvons rester silencieux \u2014 le d\u00e9veloppement de nouveaux antimicrobiens doit \u00eatre une priorit\u00e9 de sant\u00e9 publique.<\/p>\n\n\n\n<p>Une impulsion politique d\u00e9cisive, guid\u00e9e par l\u2019avis d&#8217;experts, est essentielle pour surmonter les crises de sant\u00e9 publique. La pand\u00e9mie du COVID-19 a montr\u00e9 qu&#8217;une action coordonn\u00e9e est possible \u00e0 l&#8217;\u00e9chelle nationale et internationale. Toutefois, l&#8217;attention port\u00e9e au SARS-CoV-2 a entra\u00een\u00e9 une baisse des activit\u00e9s de sensibilisation du public aux dangers de l\u2019antibior\u00e9sistance.<\/p>\n\n\n\n<p>L\u2019antibior\u00e9sistance affecte de mani\u00e8re disproportionn\u00e9e les populations des pays \u00e0 revenu faible et interm\u00e9diaire (PRFI),<sup>3,5<\/sup> o\u00f9 l&#8217;absence de moyens de pr\u00e9vention, de diagnostic et de traitement efficaces pour les maladies infectieuses se conjugue \u00e0 l&#8217;acc\u00e8s libre aux antibiotiques. En Asie du Sud et en Am\u00e9rique latine, o\u00f9 l&#8217;acc\u00e8s aux antibiotiques de deuxi\u00e8me intention est bon, le fardeau de l\u2019antibior\u00e9sistance est caus\u00e9 par des niveaux \u00e9lev\u00e9s de r\u00e9sistance.<sup>6<\/sup> Des collaborations mondiales telles que l\u2019Alliance quadripartite<sup>7<\/sup> et le <em>Global Leaders Group<\/em><sup>8<\/sup> promeuvent l&#8217;approche Une seule sant\u00e9 ou <em>One Health<\/em> fin d&#8217;am\u00e9liorer la sensibilisation et la surveillance de l\u2019antibior\u00e9sistance \u00e0 l&#8217;\u00e9chelle internationale.<\/p>\n\n\n\n<div style=\"height:31px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:25px\"><strong><em>One Health<\/em> &#8211; le probl\u00e8me et la solution<\/strong><\/p>\n\n\n\n<div style=\"height:29px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Le concept <em>One Health<\/em> vise \u00e0 assurer un \u00e9quilibre durable entre la sant\u00e9 humaine, animale et environnementale. Dans le contexte de l\u2019antibior\u00e9sistance, il s&#8217;agit d&#8217;une approche multidisciplinaire et multisectorielle visant \u00e0 pr\u00e9venir les maladies infectieuses \u00e9mergentes et r\u00e9\u00e9mergentes.<\/p>\n\n\n\n<p>Les voies potentielles du d\u00e9veloppement de l\u2019antibior\u00e9sistance sont complexes et li\u00e9es \u00e0 tous les secteurs d\u2019activit\u00e9 <em>One Health<\/em> (Figure 1 &amp; Office des publications (europa.eu)), par exemple :<\/p>\n\n\n\n<ul>\n<li>La surutilisation et le mauvais usage des antimicrobiens dans les milieux m\u00e9dicaux et v\u00e9t\u00e9rinaires,<sup>9<\/sup><\/li>\n\n\n\n<li>L&#8217;utilisation non r\u00e9glement\u00e9e et non contr\u00f4l\u00e9e d&#8217;antimicrobiens en agriculture,<sup>10<\/sup> entra\u00eenant en particulier une r\u00e9sistance aux antifongiques,<sup>11<\/sup><\/li>\n\n\n\n<li>Les r\u00e9servoirs environnementaux d\u2019antibior\u00e9sistance (par exemple, les eaux us\u00e9es et les d\u00e9chets non trait\u00e9s qui atteignent les r\u00e9servoirs d\u2019eau).<sup>5<\/sup><\/li>\n<\/ul>\n\n\n\n<div style=\"height:38px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><a href=\"https:\/\/www.cdc.gov\/narms\/images\/antibiotic-resistance-spread-300px.jpg?_=61088?noicon\"><img fetchpriority=\"high\" decoding=\"async\" width=\"750\" height=\"662\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/2-how_antibiotic_resistance_spreads.jpg\" alt=\"\" class=\"wp-image-29131\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/2-how_antibiotic_resistance_spreads.jpg 750w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/2-how_antibiotic_resistance_spreads-300x265.jpg 300w\" sizes=\"(max-width: 750px) 100vw, 750px\" \/><\/a><figcaption class=\"wp-element-caption\"><strong>Figure 1: Examples of how antimicrobial resistance spreads (<a href=\"https:\/\/www.cdc.gov\/narms\/faq.html\" target=\"_blank\" rel=\"noreferrer noopener\">CDC; National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS)<\/a>)<\/strong><\/figcaption><\/figure><\/div>\n\n\n<div style=\"height:33px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>L&#8217;approche <em>One Health<\/em> englobe diverses strat\u00e9gies de lutte contre l\u2019antibior\u00e9sistance, \u00e0 la fois scientifiques et logistiques :<\/p>\n\n\n\n<ul>\n<li>Le d\u00e9veloppement de nouveaux antimicrobiens, d&#8217;outils de diagnostic pr\u00e9cis et rapides, de vaccins et d&#8217;immunoth\u00e9rapies efficaces,<\/li>\n\n\n\n<li>Une compr\u00e9hension approfondie de l\u2019antibior\u00e9sistance au niveau mol\u00e9culaire, des interactions cible-m\u00e9dicament, de l&#8217;immunologie des maladies infectieuses et de la dysbiose suite \u00e0 un traitement antibiotique,<\/li>\n\n\n\n<li>L\u2019am\u00e9lioration des programmes de gestion des antimicrobiens et de pr\u00e9vention des infections, l\u2019efficacit\u00e9 des programmes actuels \u00e9tant insuffisante,<sup>12<\/sup><\/li>\n\n\n\n<li>Am\u00e9lioration de l&#8217;acc\u00e8s aux ressources existantes en soins de sant\u00e9, une meilleure gestion de la cha\u00eene d&#8217;approvisionnement d\u2019antimicrobiens et une r\u00e9duction de l&#8217;exposition environnementale aux r\u00e9sidus antibiotiques,<\/li>\n\n\n\n<li>Am\u00e9lioration de la surveillance en sant\u00e9 publique et de la formation du personnel de sant\u00e9 au niveau mondial.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:34px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:25px\"><strong>Le financement, une composante essentielle<\/strong><\/p>\n\n\n\n<div style=\"height:41px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>La mobilisation des ressources est n\u00e9cessaire pour l\u2019innovation. Cependant, \u00e0 l&#8217;heure actuelle, la recherche et d\u00e9veloppement (R&amp;D) d\u2019antimicrobiens est fragment\u00e9e et p\u00e2tit d\u2019un manque de collaboration entre les universit\u00e9s, l&#8217;industrie et les cliniciens. <a rel=\"noreferrer noopener\" href=\"https:\/\/carb-x.org\" target=\"_blank\">CARB-X<\/a> et le <em><a rel=\"noreferrer noopener\" href=\"https:\/\/www.amractionfund.com\" target=\"_blank\">AMR Action Fund<\/a><\/em> sont de bons exemples de sources de financement essentielles pour le d\u00e9veloppement de nouveaux antimicrobiens. Tout nouveau financement public ou priv\u00e9 doit \u00eatre largement annonc\u00e9 pour prouver que la R&amp;D d&#8217;antimicrobiens est une priorit\u00e9 mondiale.<\/p>\n\n\n\n<p>Une interruption du financement R&amp;D peut entrainer l&#8217;abandon de projets, emp\u00eacher la croissance de nouvelles entreprises et entrainer un exode des chercheurs acad\u00e9miques et industriels vers des march\u00e9s plus stables et lucratifs. L&#8217;effondrement d&#8217;entreprises dont la commercialisation de nouveaux antibiotiques n\u2019a pas emp\u00each\u00e9 la faillite (par exemple Melinta Therapeutics et Achaogen), contribue au manque de confiance dans l&#8217;investissement R&amp;D pour les antimicrobiens.<\/p>\n\n\n\n<p>En r\u00e9action, des programmes de financement ont \u00e9t\u00e9 lanc\u00e9s au Royaume-Uni<sup>13<\/sup> et aux \u00c9tats-Unis<sup>14<\/sup> pour r\u00e9compenser les entreprises qui lancent de nouveaux antimicrobiens par le biais d&#8217;une redevance annuelle fixe, en dissociant la r\u00e9compense financi\u00e8re du volume des prescriptions. Pour encourager les laboratoires pharmaceutiques internationaux \u00e0 r\u00e9investir dans la R&amp;D dans ce domaine, des programmes similaires doivent \u00eatre propos\u00e9s \u00e0 l&#8217;\u00e9chelle mondiale.<\/p>\n\n\n\n<p>Outre le financement de la R&amp;D, il est n\u00e9cessaire de soutenir la main-d&#8217;\u0153uvre sp\u00e9cialis\u00e9e dans les antimicrobiens. Les gouvernements peuvent cr\u00e9er des financements \u00e0 destination de Jeunes \u00e9quipes dans le domaine de l\u2019antibior\u00e9sistance, proposer des formations dans l&#8217;innovation de th\u00e9rapies et de prophylaxie antimicrobiennes et cr\u00e9er des centres de recherche sur l\u2019antibior\u00e9sistance (nationaux\/internationaux) qui serviraient de p\u00f4les R&amp;D.<\/p>\n\n\n\n<div style=\"height:45px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:25px\"><strong>Conclusion<\/strong><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>La lutte contre l\u2019antibior\u00e9sistance \u00e0 l&#8217;\u00e9chelle mondiale n\u00e9cessitera une r\u00e9ponse int\u00e9gr\u00e9e, collaborative et multisectorielle, un financement consid\u00e9rable et continu ainsi qu&#8217;un leadership d\u00e9cisif et un soutien ferme de la part des gouvernements, des leaders mondiaux en la mati\u00e8re, des universit\u00e9s, de l&#8217;industrie et des organismes \u00e0 but non lucratif. Les initiatives politiques en mati\u00e8re d\u2019antibior\u00e9sistance doivent \u00eatre audacieuses, innovantes, coordonn\u00e9es et durables.<\/p>\n\n\n\n<div style=\"height:34px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:34px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:25px\"><strong>R\u00e9f\u00e9rences<\/strong><\/p>\n\n\n\n<div style=\"height:4px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p style=\"font-size:15px\"><em>1. Mendelson M, Sharland M, Mpundu M. Antibiotic resistance: Calling time on the \u2018silent pandemic\u2019. JAC Antimicrob Resist 2022; 4:dlac016<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>2. Laxminarayan R. The overlooked pandemic of antimicrobial resistance. Lancet 2022;399:606\u20137.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>3. O\u2019Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance 2016.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>4. World Bank Group. Drug-resistant infections: a threat to our economic future 2017.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>5. World Health Organization. Technical brief on water, sanitation, hygiene and wastewater management to prevent infections and reduce the spread of antimicrobial resistance 2020.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>6. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022;399:629\u201355.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>7. Quadrapartite Collaboration. One health joint plan of action working together for the health of humans, animals, plants and the environment 2022.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>8. Global Leaders Group on AMR. Priorities of the global leaders group on AMR for 2021-2022 2021.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>9. McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. Microbiol Spectr 2018;6.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>10. Taylor P, Reeder R. Antibiotic use on crops in low and middle-income countries based on recommendations made by agricultural advisors. CABI Agric Biosci 2020;11:1\u201314.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>11. Miller SA, Ferreira JP, LeJeune JT. Antimicrobial use and resistance in plant agriculture: A one health perspective. Agriculture, 12(2):289.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>12. Poluektova O, Robertson DA, Rafferty A, Cunney R, Lunn PD. A scoping review and behavioural analysis of factors underlying overuse of antimicrobials. JAC Antimicrob Resist 2023; 4:dlad043,<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>13. Mahase E. UK launches subscription style model for antibiotics to encourage new development. BMJ 2020;369:m2468.<\/em><\/p>\n\n\n\n<p style=\"font-size:15px\"><em>14. Press release: Bennet, Young, Doyle, Ferguson Introduce PASTEUR Act to Fight Antimicrobial Resistance 2021.<\/em><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Auteurs<\/h3>\n\n\n\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile\" style=\"grid-template-columns:24% auto\"><figure class=\"wp-block-media-text__media\"><img decoding=\"async\" width=\"388\" height=\"388\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Derry-Mercer.jpg\" alt=\"\" class=\"wp-image-29135 size-full\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Derry-Mercer.jpg 388w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Derry-Mercer-300x300.jpg 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Derry-Mercer-150x150.jpg 150w\" sizes=\"(max-width: 388px) 100vw, 388px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong>Derry Mercer<\/strong><\/p>\n\n\n\n<p><em>Responsable du Programme Antimicrobiens\/Antimicrobial Programme Head<\/em><\/p>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile\" style=\"grid-template-columns:24% auto\"><figure class=\"wp-block-media-text__media\"><img decoding=\"async\" width=\"400\" height=\"400\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Cyril-Guyard-photo.jpg\" alt=\"\" class=\"wp-image-29139 size-full\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Cyril-Guyard-photo.jpg 400w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Cyril-Guyard-photo-300x300.jpg 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/Cyril-Guyard-photo-150x150.jpg 150w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong>Cyril Guyard<\/strong><\/p>\n\n\n\n<p><em>Directeur Scientifique, Direction Scientifique et technologique\/Chief Scientific Officer<\/em><\/p>\n<\/div><\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Traduit en Fran\u00e7ais avec www.DeepL.com\/Translator (version gratuite), \u00e9dit\u00e9 par Loane Serrano et Rapha\u00eblle Ripoche<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile\" style=\"grid-template-columns:32% auto\"><figure class=\"wp-block-media-text__media\"><a href=\"https:\/\/www.bioaster.org\/fr\/\"><img loading=\"lazy\" decoding=\"async\" width=\"250\" height=\"146\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/logo-bioaster.png\" alt=\"\" class=\"wp-image-29143 size-full\"\/><\/a><\/figure><div class=\"wp-block-media-text__content\">\n<p><strong><a href=\"https:\/\/www.bioaster.org\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">BIOASTER<\/a>, le premier Institut d\u2019Innovation Technologique en Microbiologie.<\/strong><br>Favoriser, acc\u00e9l\u00e9rer et apporter une nouvelle valeur ajout\u00e9e aux projets collaboratifs, avec des partenaires publics et priv\u00e9s, pour mieux r\u00e9pondre aux enjeux de sant\u00e9 globale.<\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019antibior\u00e9sistance, une pand\u00e9mie &#8220;silencieuse&#8221; ou &#8220;n\u00e9glig\u00e9e&#8221;,1,2 est consid\u00e9r\u00e9e par l&#8217;Organisation mondiale de la sant\u00e9 (OMS) comme une menace mondiale pour la sant\u00e9 et le d\u00e9veloppement. Si rien n&#8217;est fait, l\u2019antibior\u00e9sistance pourrait causer la mort de 10 millions de personnes par an d&#8217;ici 2050,3 co\u00fbter 100 milliards de dollars \u00e0 l&#8217;\u00e9conomie mondiale1 et plonger 28 millions [&hellip;]<\/p>\n","protected":false},"author":271,"featured_media":29149,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[3341],"tags":[6607,6673,6675],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-14T14:42:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T14:02:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"776\" \/>\n\t<meta property=\"og:image:height\" content=\"388\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Loane Serrano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Loane Serrano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\"},\"author\":{\"name\":\"Loane Serrano\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61\"},\"headline\":\"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse\",\"datePublished\":\"2023-09-14T14:42:50+00:00\",\"dateModified\":\"2025-02-26T14:02:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\"},\"wordCount\":1281,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg\",\"keywords\":[\"Antibior\u00e9sistance\",\"Edito\",\"partenaire industriel\"],\"articleSection\":[\"Editoriaux\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\",\"name\":\"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg\",\"datePublished\":\"2023-09-14T14:42:50+00:00\",\"dateModified\":\"2025-02-26T14:02:38+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg\",\"width\":776,\"height\":388},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editoriaux\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61\",\"name\":\"Loane Serrano\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/","og_locale":"fr_FR","og_type":"article","og_title":"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2023-09-14T14:42:50+00:00","article_modified_time":"2025-02-26T14:02:38+00:00","og_image":[{"width":776,"height":388,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg","type":"image\/jpeg"}],"author":"Loane Serrano","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Loane Serrano","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/"},"author":{"name":"Loane Serrano","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61"},"headline":"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse","datePublished":"2023-09-14T14:42:50+00:00","dateModified":"2025-02-26T14:02:38+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/"},"wordCount":1281,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg","keywords":["Antibior\u00e9sistance","Edito","partenaire industriel"],"articleSection":["Editoriaux"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/","name":"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg","datePublished":"2023-09-14T14:42:50+00:00","dateModified":"2025-02-26T14:02:38+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2023\/09\/tinywow_Derry-Mercer_34426921.jpg","width":776,"height":388},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/la-resistance-aux-antimicrobiens-une-pandemie-silencieuse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Editoriaux","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/edito\/"},{"@type":"ListItem","position":3,"name":"La r\u00e9sistance aux antimicrobiens : une pand\u00e9mie silencieuse"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/7993978f184ff491165415f02259de61","name":"Loane Serrano"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 15:32:42","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/29129"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/271"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=29129"}],"version-history":[{"count":17,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/29129\/revisions"}],"predecessor-version":[{"id":30141,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/29129\/revisions\/30141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/29149"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=29129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=29129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=29129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}